Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 13/20 | 0.53 |
| ▸ | PYGM | P11217 | 13/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199019 | 0.90 | PYGM (0.52) | PYGLPYGMTDP1L3MBTL1TP53 | |
| SCHEMBL6432016 | 0.89 | L3MBTL1 (0.61) | PYGLPYGMTDP1L3MBTL1TP53 | |
| SCHEMBL6435067 | 0.88 | PYGL (0.57) | PYGLPYGMTDP1L3MBTL1TP53 | |
| SCHEMBL6438952 | 0.88 | PYGL (0.56) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL6435759 | 0.87 | PYGL (0.55) | PYGLPYGMTDP1L3MBTL1NPSR1 | |
| SCHEMBL6431255 | 0.85 | LMNA (0.64) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL6430909 | 0.84 | PYGM (0.67) | PYGLPYGMTDP1KDM4ELMNA | |
| SCHEMBL6440435 | 0.83 | PYGL (0.51) | PYGLPYGMTDP1L3MBTL1KDM4E | |
| SCHEMBL6434133 | 0.82 | POLB (0.66) | PYGLPYGMTDP1KDM4ELMNA | |
| SCHEMBL7116945 | 0.81 | PYGM (0.71) | PYGLPYGMTDP1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | PYGL 1/4885PYGM 3/4885TDP1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.